Amylyx Pharmaceuticals has announced positive top-line results from its pivotal Phase 3 LUCIDITY trial evaluating avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist being...
Pharmaceutical giants Merck and Modernarevealed encouraging results from their Phase 3 INTerpath-001 study, testing an individualized mRNA cancer vaccine alongside Merck's immunotherapy drug Keytruda in melanoma patients.
The...